Cell of Origin
The cellular origin of the tumour cells in HL remained elusive for many years but microdissection coupled with analysis of immunoglobulin (Ig) genes revealed that these cells are usually clonal B-cells. HRS cells, from nearly all cHL cases, and LP cells have detectable rearrangements of Ig heavy and/or light chain genes, confirming a B-cell origin 5, 6 and, in any given case, the rearrangements are identical, proving the clonal nature of the disease. 5, 7, 8 Furthermore, the Ig variable (IgV) gene regions show evidence of somatic hypermutation, revealing a germinal centre (GC) or post-GC origin. 9 The cHL and B-cell non-Hodgkin lymphoma (B-NHL) components of composite lymphomas generally harbour identical IgV gene rearrangements but have distinct somatic Ig gene mutations. This strongly suggests that both have arisen from a common precursor which is a pre-GC or GC B-cell. 10 In LP cells intraclonal IgV gene diversity is observed indicating on-going somatic hypermutation whereas HRS cells show identical somatic hypermutations consistent with a later stage of B-cell differentiation. 5, 7, 8 "Crippling" mutations, resulting in non-functional Ig genes, are observed in around 25% of cHL cases. 5, 7, 10, 11 Rarely (<2%) HRS cells harbour rearranged T-cell receptor genes suggesting a T-cell origin in a small minority of cases.
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The phenotype of the HRS cell does not reveal its B-cell origin. Markers of Blineage, such as CD20, CD19, CD79 and surface Ig, and the transcription factors OCT2, BOB1 and PU1 are generally down-regulated in the HRS cell. 15, 16 Expression of the B-cell-specific transcription factor PAX5 is usually retained, albeit at low levels, and can be helpful in distinguishing cHL from Tcell lymphomas. 17 HRS cells classically express the tumour-necrosis factor-
This change addresses part of point 3 in that it explains the evolution of the HRS cell in relation to B cell and B-NHL and promote a favourable cellular environment through the release of multiple cytokines and chemokines (see below.) found to be a translocation partner in NLPHL, but only infrequently in cHL. 66, 67 Other genes commonly associated with Ig translocations in B-NHL, including cyclin D1, BCL2 and MYC are not implicated in HL, where the partner genes are yet to be discovered. Biological overlap with B-NHL specimens. Much further work remains to be done to characterise these cells and determine whether they are clonogenic as well as clonotypic. which may act to recruit eosinophils, which are frequently present in HL tissue. 89 The eosinophils secrete TGFβ, and express CD30 ligand which stimulates CD30 expressed on the tumour cell surface 90 . Mast cells present in the infiltrate also express CD30 ligand, and in addition may contribute to angiogenesis. 91 Other cytokines involved in the pathogenesis of HL include IL-13, which is produced by HRS cells in some cases and, since the IL-13 receptor is also expressed by HRS cells, may function in an autocrine manner to promote HRS cell survival.
Reprogramming of HRS cells

Chromosomal genetic abnormalities in the HRS cell
Interaction with the cellular microenvironment
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Gene expression studies have demonstrated that the genes most highly upregulated in HL include those encoding key cytokines such as TARC and Galectin 1, thus confirming their importance in disease pathogenesis 62, 94 Proteomic analysis of cell lines and primary tissue has also revealed elevated levels of TARC, IL1R2, MIF, CD26, CD44, and cathepsin S. 95 A summary of these, and other, molecules implicated in the cross-talk between HRS cells and their micro-environment is given in the virus remains latent in memory B-cells for the lifetime of the host. 117 and is kept in check by the cytotoxic T-lymphocyte (CTL) response. 118 Although viral infection is usually asymptomatic, EBV is associated with a number of cancers including cHL and some B-NHLs.
A proportion of cases of HL are associated with EBV, where the virus is believed to play a causal role. 4 In EBV-associated tumours, EBV is detected in all of the HRS cells (see Figure 1) and the viral infection is clonal, proving that infection occurred prior to transformation and supporting a causative role. [119] [120] [121] . resistance through down-regulation of p53, EGR1 and STAT1. 129 The BARTs are a group of alternatively spliced RNAs derived from the BamHI A fragment of the EBV genome, which encode a large number of microRNAs. At present, their function is poorly understood but it would seem likely that they have a role in viral pathogenesis.
Although the morphology, phenotype and gene expression profile of EBVassociated and non-associated cases of cHL appear similar, there is increasing evidence that the molecular pathogenesis of these two groups of cases is distinct. First, mutations of genes encoding inhibitors of NF-κB, in particular TNFAIP3 (A20), are more common in EBV-negative cases suggesting that these mutations substitute for LMP-1 expression 46 .
Secondly, crippling mutations of Ig genes appear almost exclusive to EBVassociated cases indicating that EBV is required to rescue cells harbouring these mutations from apoptosis. Thirdly, expression of multiple receptor tyrosine kinase pathways 130 is more frequent in non-EBV-associated cases, suggesting that EBV is replacing vital oncogenic signals.
Epidemiological data also support a role for EBV in HL pathogenesis. The proportion of EBV-associated cHL cases is significantly higher in cases occurring in early childhood and older adult age groups (aged >50 years) compared to younger adults, in developing countries compared to industrialised countries, and in males compared to females., 131, 132 Cases of mixed-cellularity subtype are also significantly more likely to be EBVassociated than nodular sclerosis cases. There is an increased risk of EBV-associated HL following infectious mononucleosis, 133, 134 which decreases with increasing time from the illness.
The frequency of circulating EBV-infected cells is also significantly higher in pre-treatment blood samples from EBV-associated cases when compared with non-EBV-associated cases, 135 and patients with HL also have been shown to have higher titres of anti-EBV antibody both at time of diagnosis and several years prior. 136 Collectively, these data suggest that control of EBV infection is related to risk of developing EBV-associated HL.
The immune response and cHL
An association between cHL, particularly EBV-associated disease, and 
Conclusions
The molecular pathogenesis of HL is complex; however, this remarkable disease is beginning to give up its secrets. There is good evidence that HL is 
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